A New Decade of ME Research: The 11th Invest in ME International ME Conference 2016
Mark Berry presents the first in a series of articles on the 11th Invest in ME International ME Conference in London ...
Discuss the article on the Forums.

Blisibimod for B-Cell Mediated Autoimmune Disease

Discussion in 'Other Health News and Research' started by merylg, Dec 4, 2011.

  1. merylg

    merylg Senior Member

    Messages:
    797
    Likes:
    578
    Sydney, NSW, Australia
    http://www.bioportfolio.com/news/ar...nterim-B-cell-Analysis-Of-Pearl-sc-Study.html

    "About B-Cell Activating Factor (BAFF) and blisibimod

    BAFF has been associated with a wide range of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF's potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of blisibimod, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. Blisibimod is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to blisibimod in all potential indications."
     

See more popular forum discussions.

Share This Page